


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX0489US.NP
Inventors: Duan et al.
Serial No.: 10/558,543
Filing Date: Not Assigned
Examiner: Not Assigned
Customer No.: 32800
Group Art Unit: Not Assigned
Confirmation No.: 6173
Title: Cln101 Antibody Compositions and Methods
of Use Alone and in Combination with
Prostate Specific Antigen and Other
Cancer Markers

Electronically Submitted via EFS-Web

Date: June 21, 2007

I hereby certify that this paper is being electronically
submitted on the date indicated above to the
Commissioner for Patents, U.S. Patent &
Trademark Office

By 
Typed Name: Kathleen A. Tyrrell, Reg. No. 38,350

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R.
§§1.97-1.98, information relating to the above-identified
application is hereby disclosed. Inclusion of information in
this statement is not to be construed as an admission that this
information is material as that term is defined in 37 C.F.R.
§1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is attached hereto; or

() Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in §1.17(p) is provided.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I) (1).


(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith with the exception of U.S. Patents and U.S. Published Applications.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

(XX) A copy of the Invitation to Pay Additional Fees and, Where Applicable, Protest Fee from PCT Application No. PCT/US2004/16969, which corresponds to this U.S. Patent Application is included.

(XX) All listed references are in the English language.

Respectfully submitted,

Kathleen A. Tyrrell
Registration No. 38,350

Date: June 21, 2007

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515